Welcome to the e-CCO Library!

P507: Vulvar Crohn’s disease: A challenging diagnosis
Year: 2021
Source: ECCO'21 Virtual
Authors: Sahar, N.(1);Dahmani, W.(1);Nour, E.(1);Aya, H.(1);Wafa, B.A.(1);Aida, B.S.(1);Ahlem, B.(1);Mehdi, K.(1);Hanene, J.(1);Ali, J.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P507: What is the impact of infliximab metaoptimisation on surgical rates and need-to-change-therapy in real-world practice for severe inflammatory bowel disease?
Year: 2018
Source: ECCO '18 Vienna
Authors:

T. Lefebvre1, R. Cormons1, J.-L. Faucheron2, M. Baudrant3, B. Bonaz1, N. Mathieu4*

Created: Thursday, 21 February 2019, 9:14 AM
P508 Safety and efficacy of combining biological therapies together or with small molecules in patients with inflammatory bowel disease: A retrospective multicentre national observational case series study
Year: 2020
Source:

ECCO'20 Vienna

Authors:

L. Goessens1, J.F. Colombel2, A. Outtier3, M. Ferrante3, M. Truyens4, T. Lobaton4, F. Baert5, P. Bossuyt6, A. Cremer7, E. Macken8, B. Strubbe9, J.F. Rahier1

Created: Thursday, 30 January 2020, 10:12 AM
P508: Association between clinical outcome and post induction CT-P13 trough levels at week 14, in patients with inflammatory bowel disease. Preliminary results in an observational multicentric study
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Elosua González A.*1, Oyόn Lara D.1, Nantes Castillejo Ó.1, Ogueta Fernández M.Ά.2, Gutiérrez Mendizábal P.3, Muñoz Villafranca M.C.3, Gόmez Irwin L.4, Muñagorri Santos A.I.5, Rodríguez Lago I.6, Rodríguez Gutiérrez C.1 IBD Study Group from the Basque-Navarre Society of Gastrointestinal Diseases

Created: Wednesday, 20 February 2019, 10:36 AM
P508: Does corticosteroid therapy affect prognosis in inflammatory bowel disease patients hospitalised with Clostridium difficile infection?
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

H. Bar Yoseph1,2, H. Daoud3, D. Ben Hur1, Y. Chowers1,2, M. Waterman*1,2

Created: Friday, 22 February 2019, 9:41 AM
P508: Dose adjustment in patients with moderate to severe ulcerative colitis: results from year 3 of the UNIFI maintenance study long-term extension
Year: 2021
Source: ECCO'21 Virtual
Authors: Rowbotham, D.S.(1);Scherl, E.J.(2);Sands, B.E.(3);Panaccione, R.(4);Peyrin-Biroulet, L.(5);Zhang, H.(6);Miao, Y.(6);Leong, R.W.(7);Afif, W.(8);Arasaradnam, R.P.(9);Danese, S.(10);Marano, C.(6);
Created: Wednesday, 2 June 2021, 4:12 PM
P508: Pregnancy outcomes in patients with inflammatory bowel disease experiencing flare ups during foetal development
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

Y. Yokoyama*1, H. Tanaka2, T. Miyazaki1, T. Sato1, M. Kawai1, Y. Kita1, K. Kamikozuru1, M. Iimuro1, N. Hida1, S. Nakamura1

Created: Friday, 22 February 2019, 9:49 AM
P508: Response of hepatitis B vaccination in patients with inflammatory bowel disease; prospective observational study in Korea
Year: 2018
Source: ECCO '18 Vienna
Authors:

J.Y. Chang*, S.-A. Jung, C.M. Moon, S.-E. Kim, H.-K. Jung, K.-N. Shim

Created: Thursday, 21 February 2019, 9:14 AM
P508: Sarcopenia is associated with increased rates of infectious post-operative complications in Crohn's disease patients
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Simpson, K.(1)*;Inniss, S.(2);Fragkos, K.C.(1);Wood, C.P.J.(1);Smith, A.(2);Rahman, F.Z.(1);
Created: Friday, 14 July 2023, 11:05 AM
P508: The impact of disease duration and early biologic treatment on transmural healing in Crohn’s disease
Year: 2022
Source: ECCO'22
Authors: Revés, J.(1);Freire, G.(2);Sousa, P.(2);Primitivo, A.(2);Nascimento, C.(1);Morão, B.(1);Abreu, N.(3);Palmela, C.(1);Glória, L.(1);Torres, J.(1);
Created: Friday, 11 February 2022, 3:56 PM
P509 Vedolizumab levels in breast milk: Results from a prospective, postmarketing, milk-only lactation study in nursing mothers with inflammatory bowel disease
Year: 2020
Source:

ECCO'20 Vienna

Authors:

W. Sun1, B. Fennimore2, D.B. Beaulieu3, R. Arsenescu4, A. Stein5, J. Chen6, T. Lin7, S. McKnight8, M. Rosario9, R.A. Lirio10

Created: Thursday, 30 January 2020, 10:12 AM
P509: Biomarkers of neutrophil activity and extracellular matrix turnover predict long-term response to vedolizumab in patients with Crohn’s disease
Year: 2022
Source: ECCO'22
Authors: Sorokina Alexdóttir , M.(1);Bourgonje , A.R.(2);Karsdal , M.A.(1);Bay-Jensen , A.C.(1);Pehrsson , M.(1);Loveikyte , R.(2);van Dullemen , H.M.(2);Visschedijk , M.C.(2); A. M. Festen , E.(2);K. Weersma , R.(2);Faber , K.N.(2);Dijkstra , G.(2);Joachim H. , M.(1);
Created: Friday, 11 February 2022, 3:56 PM
P509: IBD cancer and serious infections in Europe (I-CARE): a European prospective observational study
Year: 2017
Source: ECCO '17 Barcelona
Authors:

The I-CARE Study Group

Created: Wednesday, 20 February 2019, 10:36 AM
P509: Influence of concomitant immunosuppresives in retention rate in Crohn´s Disease patients under ustekinumab in the SUSTAIN Study
Year: 2021
Source: ECCO'21 Virtual
Authors: Chaparro, M.(1);Bastón Rey, I.(2);Fernández-Salgado, E.(3);González García, J.(4);Ramos, L.(5);Diz-Lois Palomares, M.T.(6);Argüelles, F.(7);Iglesias Flores, E.(8);Cabello, M.(9);Rubio Iturria, S.(10);Núñez Ortiz, A.(11);Charro, M.(12);Ginard, D.(13);Dueñas Sadornil, C.(14);Merino Ochoa, O.(15);Busquets, D.(16);Iyo, E.(17);Gutiérrez Casbas, A.(18);Ramírez de la Piscina, P.(19);Boscá-Watts, M.M.(20);Arroyo, M.(21);García, M.J.(22);Hinojosa, E.(23);Gordillo, J.(24);Martínez Montiel, P.(25);Velayos Jiménez, B.(26);Quílez Ivorra, C.(27);Vázquez Morón, J.M.(28);Huguet, J.M.(29);González Lama, Y.(30);Muñagorri Santos, A.I.(31);Amo, V.M.(32);Martín Arranz, M.D.(33);Bermejo, F.(34);Martínez Cadilla, J.(35);Fradejas Salazar, P.(36);Novella, C.(37);Vispo, E.(37);Barreiro-de Acosta, M.(2);Gisbert, J.P.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P509: Long-term outcomes in biologic-treated perianal Crohn’s fistula
Year: 2018
Source: ECCO '18 Vienna
Authors:

S. Adegbola1*, W.Y. Mak2, K. Sahnan1, P. Tozer1,3, P. Bassett4, S. Hiles5, R. Phillips1, J. Warusavitarne1,3, O. Faiz1,3, A. Hart1,2

Created: Thursday, 21 February 2019, 9:14 AM
P509: Long-term outcomes of adalimumab in patients with Crohn’s disease: Can a doubled dose of adalimumab improve outcomes?
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

J. Kanazawa*1, K. Yokoyama1, Y. Matsumoto1, K. Kawagishi1, M. Mukae1, M. Kubota1, K. Kobayashi1, W. Koizumi1

Created: Friday, 22 February 2019, 9:41 AM
P509: Surgery and biologic prescription rates for Crohn's disease in Lothian, Scotland; an updated population-based cohort study.
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Jenkinson, P.(1)*;Plevris, N.(2);Lyons, M.(2);Gros Alcalde, B.(2);Derikx, L.(2);Constantine-Cooke, N.(3);Arnott, I.(2);Jones, G.(4);Lees, C.(2);
Created: Friday, 14 July 2023, 11:05 AM
P509: What is the effect of inflammatory bowel disease on sedation rates at colonoscopy?
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

M. Walshe*, C. Moran, G. Horgan, G. Cullen, H. Mulcahy, G. Doherty

Created: Friday, 22 February 2019, 9:49 AM
P510 Dose escalation of subcutaneous vedolizumab in patients with ulcerative colitis: A post hoc analysis of the VISIBLE trial data
Year: 2020
Source:

ECCO'20 Vienna

Authors:

W. Sandborn1, D. Wolf2, G. D’haens3, J. Jansson4, J. Chen5, S. Uddin5, N. Candela6, K. Lasch6, K. Kisfalvi5

Created: Thursday, 30 January 2020, 10:12 AM
P510: Assessment of study group – patients with inflammatory bowel disease, treated with monoclonal anti-TNF alpha: a multicenter, prospective cohort observational study, Satimos – preliminary report in pediatric population
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Jarzebicka D.*1, Sieczkowska J.1, Borys-Iwanicka A.2, Korlatowicz-Bilar A.3, Szaflarska-Popławska A.4, Grzybowska-Chlebowczyk U.5, Łazowska-Przeorek I.6, Daniluk U.7, Korczowski B.8, Sordyl B.9, Szczepanik M.10, Landowski P.11, Plocek A.12, Bąk-Drabik K.13, Zagόrowicz E.14, Kierkus J.1

Created: Wednesday, 20 February 2019, 10:36 AM